IDXX · Q1 2026 Earnings

Bullish

Idexx Laboratories

Reported May 5, 2026

30-second summary

30-second take: Q1 revenue of $1.141B grew 14.3% YoY with CAG Diagnostics recurring +14.1% reported / 11.0% organic. Idexx raised every line of the FY26 guide one quarter into the year: revenue midpoint +$42M (company-stated; $41.5M precise) to $4.7175B (reported growth 8.6–10.6%, +100bps at midpoint), GAAP EPS midpoint +$0.13 to $14.675, and CAG Dx recurring reported growth to 9.6–11.6% (+100bps). The pattern from FY25 — initial conservative bar, sequential raises through the year — is repeating, with the U.S. CAG Dx premium to clinical visits now at ~1,100bps and the diagnostic-frequency-over-visits thesis fully validated through a leadership transition.

Headline numbers

EPS

Q1 FY2026

$3.30

Revenue

Q1 FY2026

$1.14B

+14.3% YoY

Gross margin

Q1 FY2026

63.4%

Free cash flow

Q1 FY2026

$0.23B

Operating margin

Q1 FY2026

31.8%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$1.14B	+14.3%	$1.09B	+4.6%
EPS	$3.30	—	$2.92	+13.0%
Gross margin	63.4%	—	60.3%	+310bps
Operating margin	31.8%	—	28.9%	+290bps
Free cash flow	$0.23B	—	—	—

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q1 FY2026	7.6% to 9.6% reported growth	14.3% YoY growth	+4.7-6.7 pts above guide	Beat
Revenue (Organic)	Q1 FY2026	7.0% to 9.0% organic growth	Not disclosed	Implied above 9% range	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2026	$4,632M - $4,720M	$4,675M - $4,760M	+$43M low, +$40M high	Raised
Revenue growth (reported)	FY2026	7.6% - 9.6%	8.6% - 10.6%	+100 bps (low and high end)	Raised
Revenue growth (organic)	FY2026	7.0% - 9.0%	7.7% - 9.7%	+70 bps (low), +70 bps (high)	Raised
CAG Diagnostics recurring revenue growth (reported)	FY2026	8.6% - 10.6%	9.6% - 11.6%	+100 bps (low and high end)	Raised
CAG Diagnostics recurring revenue growth (organic)	FY2026	8.0% - 10.0%	8.7% - 10.7%	+70 bps (low and high end)	Raised
Operating margin	FY2026	32.0% - 32.5%	32.1% - 32.5%	+10 bps low end	Raised
Operating margin expansion	FY2026	40 - 90 bps	50 - 90 bps	+10 bps low end	Raised
EPS growth (reported)	FY2026	9% - 13%	11% - 14%	+200 bps low, +100 bps high	Raised
EPS growth (comparable)	FY2026	10% - 14%	11% - 15%	+100 bps	Raised

Reaffirmed unchanged this quarter: EPS (GAAP) ($14.45 - $14.90)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
CAG (Companion Animal Group)	$1.054B	+14.6%
Water	$0.05B	+10.9%
LPD (Livestock, Poultry and Dairy)	$0.032B	+13.6%
CAG Diagnostics recurring revenue	$0.92B	+14.1%
CAG Diagnostics - IDEXX VetLab consumables	$0.413B	+19.7%
CAG Diagnostics - Reference laboratory services	$0.386B	+12.1%
CAG Diagnostics capital instrument revenue growth (reported)	32.7%	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
United States	$0.725B	+10.7%
International	$0.416B	+21.0%
CAG Diagnostics recurring revenue organic growth	11.0%	—
Premium instrument installed base growth	12%	—
IDEXX inVue Dx placements (quarterly)	1,100 units	—
Comparable operating margin expansion	100 basis points	—
Free cash flow conversion (TTM)	1.10x net income	—
Gross margin expansion (reported)	90 basis points	—
CAG Diagnostics International organic growth	11.7%	—

Management tone

Narrative arc: Q2 (inVue Dx ramp acceleration) → Q3 ("most successful product rollout in IDEXX history") → Q4 (visit-decline assumption hardcoded, FY26 set conservatively) → Q1 (visit-decoupling proven; CEO transition message frames diagnostics as the secular winner).

Three quarters ago wellness visit declines were the backdrop the company was lapping; last quarter management hardcoded a visit-decline assumption into the FY26 guide; this quarter management is essentially declaring victory on the decoupling. The Q1 print of U.S. CAG Dx recurring premium to clinical visits at ~1,100bps is now being positioned as the operating model, not a temporary outperformance. From the call: "U.S. same-store clinical visits declined minus 1% in the quarter, reflecting an IDEXX U.S. CAG diagnostics recurring revenue growth premium to U.S. clinical visits of approximately 1,100 basis points." Q1 came in at -1% and management revised the full-year visit assumption to -1.5%. The bull case has moved from "wait for visits to recover" two quarters ago, to "frequency expansion is the model" today.

inVue Dx framing has matured from "demand exceeding supply" two quarters ago to "scaling within plan with quarter-to-quarter choppiness." Q1's ~1,100 placements falls below the 1,375/quarter pace needed to hit the 5,500 FY target. Management's Q&A response — that Q1 reflected normal customer-mix variability between independents and corporates — is plausible but lacks the surplus-demand conviction of Q2/Q3 FY25. The framing has shifted from acceleration story to predictable platform: "InViewDx utilization continues to track well to our reoccurring revenue estimates previously provided." That language is markedly less promotional than Q3 FY25's superlatives.

CancerDx has moved from "U.S. franchise with international optionality" to "global platform with corporate adoption." The Q1 international launch in Europe and Australia landed on schedule, and management cited a large Australian corporate group including CancerDx in its senior wellness plan at no additional charge to members. From the call: "With over 7,500 practices ordering since launch, cancer DX is a major differentiator for our reference lab business." Reference lab services growth held at 12.1%, validating that CancerDx is a reference lab volume multiplier, not just a standalone test line.

FNA framing has firmed from "controlled pilot" to "platform capability with multi-indication runway." From the call: "Overall, FNA utilization is tracking to our planning assumptions, and we remain excited about the potential of FNA as a platform capability that can expand over time beyond mass cell tumor detection." The TAM math management put forward in Q&A — 12M FNA procedures performed globally with 90% of suspicious masses currently uninvestigated — is the most concrete sizing of the franchise to date and signals confidence the platform extends well beyond the initial mass cell tumor indication.

The leadership transition message — this being the outgoing CEO's final call — is unusually forward-leaning rather than cautiously backward-looking. From the call: "The fundamental drivers of this industry have never been stronger. The human animal bond continues to deepen. Diagnostics is the foundation of this evolution." A transitioning CEO booking the FY guide raise across every line and the incoming CEO emphasizing AI and commercial reach is the opposite of the typical "preserve optionality through the handoff" framing. It signals both that the outgoing leadership believes positioning is structurally sound and that the incoming leadership inherits no near-term reset.

Recurring themes management leaned on this quarter:

Diagnostics utilization expansion decoupled from visit volume trendsSoftware and AI-enabled platform scaling across cloud-native PIMS and imagingInternational market expansion and customer diversification driving recurring revenue growthPremium instrument placements and installed base growth sustainabilityOperating leverage through recurring revenue mix shift and margin expansionLeadership transition with continuity of innovation and strategy

Risks management surfaced:

U.S. clinical visits continuing to decline (guidance updated to minus 1.5% for full year)Wellness visit pressure (declined minus 3% in Q1)Rapid assay revenue headwinds from Catalyst migration (approximately 2% negative impact estimated)Foreign exchange volatility (1% USD strengthening would reduce revenue $12M and EPS 4 cents)International supply chain dynamics in Middle East impacting water business growth

Q&A highlights

Michael Ryskin · Bank of America

InView placement count of 1,099 in Q1 appears below pace for 5,500 full-year target. Asking about pacing dynamics, funnel confidence, and market receptivity assumptions.

Management reaffirmed high confidence in 5,500 placement target, attributed Q1 pace to normal quarter-to-quarter choppiness driven by customer mix (independents vs. corporates), and highlighted strong market receptivity. Clinical visits declined 1% in Q1 vs. initial guide of -2%, with positive momentum from aging pet population (5+ years old), though wellness and discretionary categories remain pressured.

Q1 InView placements: 1,099Full-year InView placement target: 5,500Q1 clinical visit decline: -1% (better than initial -2% guide)Full-year clinical visit guide: -1.5% decline

Chris Schott · JP Morgan

Two questions: (1) XUS (international) strong growth—how much is IDEXX commercial execution vs. broader market health? (2) InView F&A utilization and uptake relative to expectations; rollout timing and backlog status.

Management attributed international growth to long-term ecosystem investments (reference lab build-out, software localization, tailored solutions) rather than pure market tailwinds. F&A controlled launch is on track with positive customer feedback; broadening in Q2 and moving to unconstrained launch later in 2025. Emphasized staged approach ensures customer experience and long product tail benefits.

International growth driven by double-digit commercial expansions over five yearsF&A controlled launch proceeding as planned with positive customer feedbackF&A broadening into Q2, unconstrained launch targeted for later in 2025Staged launch model enables optimal implementation, training, and end-to-end customer experience

Erin Wright · Morgan Stanley

Consumables momentum acceleration: what portion is InView-related vs. indirect IDEXX 360 contract lock-in effects? When will InView consumables move the needle meaningfully? F&A backlog and next menu expansion timing expectations.

InView consumables (ear cytology, blood morphology) contributing directly to strong growth and represent 100% new incremental consumables. Management expects momentum to continue with F&A and benefit from large installed bases of premium instruments with rapid new parameter uptake. Noted 100-150 million cytologies performed globally annually, with long runway ahead. F&A represents complementary care episode; 90% of suspicious masses currently uninvestigated due to manual cytology burden.

InView consumables: ear cytology and blood morphology within expectationsInView consumables represent 100% new incremental growth not previously availableGlobal cytology market: 100-150 million procedures annuallyF&A addressable market: ~12 million FNAs performed, but 90% of suspicious masses uninvestigated today

John Block · Stifel

CAG DX recurring growth guide shows 10.25% in 1H but 9.7% for full year despite harder 2H comps. No material visit improvement implied from Q1. What drivers support 2H acceleration in two-year stacks without visit improvement?

Management attributed 70 bps guidance raise to continued global execution, strong innovation benefits (InViewDX, Catalyst menu additions), expanded diagnostic utilization, modest visit improvement from initial guide, and strong reference lab momentum. Emphasized instrument placement trends remain positive, diagnostic frequency/utilization expanding, and CancerDx differentiation driving reference lab growth. Guidance represents range with confidence in upper bound.

Full-year organic guidance raise: ~70 basis points at midpointCAG DX recurring guidance raised but 2H growth slightly below 1HGuidance format: range (not single point), upper bound more consistent with current trendsReference lab business momentum described as 'very strong' globally

Daniel Grossleit · Citi

CAG Diagnostics revenue outlook improvement: quantify contribution from volume vs. price vs. innovation. What's the biggest swing factor between ranges (top vs. bottom end)?

Management clarified that 70 bps guidance raise is entirely volume-driven; pricing remains flat at ~4% net price realization (U.S. modestly lower than prior). Volume drivers: business execution, innovation (InViewDX, Catalyst menu), diagnostic frequency expansion, and modest visit improvement. Growth fueled by double-digit installed base expansion, reference lab strength, and CancerDx visibility. No pricing changes.

CAG Diagnostics revenue improvement: 100% volume-drivenNet price realization: ~4% (unchanged; U.S. modestly lower than prior)Point-of-care installed base: double-digit growth sustainedReference lab business: healthy momentum

Answers to last quarter's watch list

Whether the FY26 CAG Dx recurring guide gets raised in Q1. Resolved positively. Management raised the FY26 CAG Dx recurring reported growth guide from 8.6–10.6% to 9.6–11.6% (+100bps both ends) and organic from 8.0–10.0% to 8.7–10.7% (+70bps both ends) — the conservative initial setup is now confirmed, and the FY25 pattern of through-year raises is repeating. Status: Resolved positively

U.S. CAG Dx recurring growth premium to clinical visits. Resolved positively. Q1 U.S. CAG Dx recurring premium to clinical visits ran ~1,100bps with U.S. visits at -1% (better than the -1.5% FY assumption). The structural-frequency thesis is locked in. Status: Resolved positively

inVue Dx Q1 placement run-rate. Resolved negatively. Q1 placements of ~1,100 fell below the 1,400 threshold and well short of the 1,375/quarter average needed to hit 5,500 FY. Management reaffirmed the FY target and attributed Q1 variability to customer mix, but the cushion is gone and Q2–Q4 now need to average ~1,467 placements per quarter. Status: Resolved negatively

CancerDx international revenue contribution and reference lab growth. Resolved positively. The Europe/Australia launch landed on schedule, a large Australian corporate group included CancerDx in its senior wellness plan, and reference lab services growth held at 12.1%. Total ordering practices now exceed 7,500. Status: Resolved positively

FY26 operating margin trajectory through the year. Resolved positively. Q1 reported operating margin of 31.8% landed at the high end of the FY guide range; comparable expansion of +100bps YoY exceeded the +50bps watch threshold. FY26 reported margin guide raised to 32.1–32.5% (+10bps at low end) and expansion to 50–90bps — putting the upper half of the FY range in play. Status: Resolved positively

Whether non-wellness/aging-pet visit recovery sustains. Resolved positively. Management cited a third consecutive quarter of positive trend in pets aged 5+ across both wellness and non-wellness visits. Non-well visits increased 20bps YoY in Q1 while wellness declined 3%. The aging-pet structural offset is now a confirmed three-quarter pattern. Status: Resolved positively

What to watch into next quarter

inVue Dx Q2 placement recovery. Q1 ran ~1,100 vs. the 1,375/quarter average needed for 5,500 FY. Watch whether Q2 prints above 1,400 (rebuilds cushion) or holds near 1,100 (FY target slips). Anything below 1,250 in Q2 likely forces a placement guide cut in H2.

Whether the FY26 CAG Dx recurring guide gets raised again in Q2. FY25 saw raises in both Q2 and Q3. Watch whether the now-9.6–11.6% reported guide moves up further off Q1's 14.1% print, or whether management holds to imply a more conservative 2H assumption.

U.S. CAG Dx premium to visits. Premium held at ~1,100bps in Q1. Watch whether it sustains above 1,000bps in Q2 — the threshold for the structural-frequency thesis remaining intact in 2026 modeling.

Reference lab services growth trajectory with international CancerDx. Q1 held at 12.1% with the international launch quarter-old. Watch whether Q2 accelerates above 13% as European and Australian adoption broadens, or whether the U.S. franchise carries the load alone.

Q2 operating margin print vs. the 33.9–34.3% guide. Implies a sharp QoQ step-up from Q1's 31.8% — watch whether Q2 lands at the high end (supports FY upper half) or low end (commercial investment front-loads).

FNA controlled-launch broadening update. Management committed to Q2 broadening with an unconstrained launch later in 2026. Watch whether the Q2 print includes early FNA revenue contribution color or remains framed as a pilot — and whether the second cancer biomarker addition timeline holds.

Sources

IDXX Q1 2026 press release, SEC filing (Form 8-K Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/tm2613510d1_ex99-1.htm
IDXX Q1 2026 earnings conference call (prepared remarks and Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.